Skip to main content

Novel Separation and Quantitative Determination of Levofloxacin, Prulifloxacin, Gatifloxacin, Sparfloxacin, Moxifloxacin and Balofloxacin Fluoroquinolone Antibacterials in Pharmaceutical Dosage Forms by RP-HPLC Method | Chapter 1 | Trends in Pharmaceutical Research and Development Vol. 1

For the first time, Simple, selective, sensitive RP-HPLC method developed for the separation and quantitative estimation of Levofloxacin (LEVO), Prulifloxacin (PRFX), Gatifloxacin (GATI), Sparfloxacin (SPAR), Moxifloxacin (MOXI) and Balofloxacin (BALO) relating to fluoroquinolone antibacterials in pharmaceutical dosage forms. The important advantage of the developed method was that the six separate drugs could be estimated on a single chromatographic system without modifications in detection wavelength and mobile phase by RP-HPLC. The chromatographic separation of the selected drugs carried out on Welchrom C18 column consisting of 250 mm X4.6 mm, 5 µm particle size utilizing mixture of 10 mM phosphate buffer (pH 3.1): Acetonitrile in the ratio of 70:30,v/v as mobile phase at the flow rate of 1 mL/min with detection wavelength at 293 nm by using UV spectrophotometric detector with total run time of 10 minutes and 3.613, 4.230, 4.707, 5.497, 5.880 and 6.253 minutes of retention time, 12,261, 12,554, 13,157, 14,761, 14,912 and 15,916 of plate number, 1.106, 1.067, 1.040 and 1.073, 1.030 and 1.086 tailing factors were obtained for LEVO, PRFX, GATI, SPAR, MOXI and BALO respectively. All calibration curves for six drugs showed indicated linearity over a concentration range of 2-10 µg/mL. The results regarding to limit of detection (LOD) and limit of quantitation (LOQ) for LEVO, PRFX, GATI, SPAR, MOXI and BALO were found to be 0.116 µg/mL and 0.348 µg/mL; 0.152 µg/mL and 0.460 µg/mL; 0.084 µg/mL and 0.255 µg/mL; 0.186 µg/mL and 0.558 µg/mL, 0.162 and 0.493, 0.112 and 0.390 respectively. These results                clearly show the low values of LOD and LOQ. The said proposed method utilized for quantification             of the marketed formulation. The mean assay values for LEVO, PRFX, GATI, SPAR, MOXI and BALO arrived at 99.317±0.990%, 99.9±0.04%, 99.9±0.02%, 99.45±0.01%, 99.945±0.056% and 99.68±0.09% respectively

Author(s) Details
Prof. Panchumarthy Ravisankar
Department of Pharmaceutical Analysis, Vignan Pharmacy College, Vadlamudi, Guntur District – 522 213, Andhra Pradesh, India

Dr. Ch. V. Prasada Rao
Department of Pharmaceutics, Vignan Pharmacy College, Vadlamudi, Guntur District – 522 213, Andhra Pradesh, India.

View Book: - http://bp.bookpi.org/index.php/bpi/catalog/book/156

Comments

Popular posts from this blog

A Brief Study of Middleware Technologies: Programming Applications and Management Systems | Chapter 15 | Novel Research Aspects in Mathematical and Computer Science Vol. 1

  Many platforms, services, applications, hardware, and operating systems are connected through the middleware layer. Because the middleware layer abstracts much low-level complexity and makes applications and software systems portable, it allows disparate systems to interface and function together in harmony. Middleware technologies enable software engineers to swiftly construct software systems and applications, allowing developers to focus on more important tasks. This chapter examines several types of middleware systems and discusses middleware capabilities, middleware operation, middleware's function in cloud-based systems, and the best middleware platforms to use. Middleware systems are widely utilised and can be found in practically any software system or application. Middleware programmes provide as a link between many sorts of systems and protocols. They serve as a mechanism for various systems. To successfully exchange information, it runs on a variety of operating system

A Prospective Study about Safety and Efficacy of Perioperative Lidocaine Infusion | Chapter 09 | New Horizons in Medicine and Medical Research Vol. 8

 Opioids cause clinically significant side effects such as respiratory depression, immunosuppression, muscle rigidity, negative inotropism, nausea, vomiting, hyperalgesia, urine retention, postoperative ileus, and drowsiness. Perioperative opioids are a major contributor to the United States' and other countries' opioid epidemics. Non-opioid analgesics, particularly lidocaine, are becoming more common for perioperative use as a result of this. A total of 185 adult patients were randomly assigned to one of two groups: control group I (105 patients) [fentanyl group] or group ii (80 patients) [opioid-free anaesthesia group]. Lidocaine 1.5 mg/kg bolus followed by 1.5 mg/kg/h infusion intraoperatively, and 1.5-2 mg/kg/h infusion for 2-8 hours postoperatively were given to patients in both groups at anaesthetic induction. Intraoperatively, both groups received analgesic adjuvants such as diclofenac 75 mg, paracetamol 1 gm, and mgso4 30-50 mg/kg. If the mean arterial pressure (map)

A Case Report on Delayed Diagnosis of Glioblastoma | Chapter 07 | New Horizons in Medicine and Medical Research Vol. 8

  The clinical and radiological indications of a concomitant tumour may be hidden by the rupture of a cerebral aneurysm. The goal of this study is to raise awareness about the dangers of delayed diagnosis by recounting the case of a patient who had a subarachnoid haemorrhage that hid the presence of a glioblastoma for several months. Only a few similar cases have been recorded in the literature: The therapy of two recent severe neurosurgical illnesses is discussed in this article. Author(S) Details Gabriele Ronchetti Department of Neurosurgery, Ospedale San Giovanni Bosco, ASL Cittá di Torino, Italy. Carlo Giussani Department of Surgery and Translational Medicine, San Gerardo Hospital, University of Milano Bicocca, via Pergolesi 33, 20900, Monza, Italy. View Book:- https://stm.bookpi.org/NHMMR-V8/article/view/6645